高级检索
当前位置: 首页 > 详情页

Urolithin C suppresses colorectal cancer progression via the AKT/mTOR pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Chengdu Univ Tradit Chinese Med, Sch Med & Life Sci, Chengdu 611137, Peoples R China [2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Oncol, Chengdu 610072, Peoples R China [3]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Canc Inst, Sichuan Acad Med Sci, Chengdu 610072, Peoples R China [4]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Lab Med, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Peoples R China [5]Harbin Med Univ Canc Hosp, Biotherapy Ctr, Harbin 150081, Peoples R China [6]Univ Elect Sci & Technol China, Sch Med, Chengdu 610047, Peoples R China [7]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Chengdu 610042, Peoples R China [8]Yu Yue Pathol Sci Res Ctr, Chongqing 400039, Peoples R China [9]Jinfeng Lab, Chongqing 401329, Peoples R China
出处:
ISSN:

关键词: Urolithin C Colorectal cancer progression YBX1 AKT/mTOR pathway

摘要:
Urolithin families are gut-microbial metabolites of ellagic acid (EA). Although urolithin A (UA) and urolithin B (UB) were reported to have antiproliferative activities in cancer cells, the role and related mechanisms of urolithin C (UC) in colorectal cancer (CRC) have not yet been clarified. In this study, we assess the antitumor activities of UC in vitro and in vivo and further explore the underlying mechanisms in CRC cell lines. We found that UC inhibited the proliferation and migration of CRC cells, induced apoptosis, and arrested the cell cycle at the G2/M phase in vitro, and UC inhibited tumor growth in a subcutaneous transplantation tumor model in vivo. Mechanically, UC blocked the activation of the AKT/mTOR signaling pathway by decreasing the expression of Y-box binding protein 1(YBX1). The AKT agonist SC79 could reverse the suppression of cell proliferation in UC-treated CRC cells. In conclusion, our research revealed that UC could prevent the progression of CRC by blocking AKT/mTOR signaling, suggesting that it may have potential therapeutic values.

基金:

基金编号: grant number 2023YFC3402100

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 3 区 药物化学 3 区 药学
最新[2023]版:
大类 | 4 区 医学
小类 | 3 区 药物化学 3 区 药学
JCR分区:
出版当年[2023]版:
Q3 CHEMISTRY, MEDICINAL Q3 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q3 CHEMISTRY, MEDICINAL Q3 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Chengdu Univ Tradit Chinese Med, Sch Med & Life Sci, Chengdu 611137, Peoples R China
通讯作者:
通讯机构: [1]Chengdu Univ Tradit Chinese Med, Sch Med & Life Sci, Chengdu 611137, Peoples R China [2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Oncol, Chengdu 610072, Peoples R China [3]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Canc Inst, Sichuan Acad Med Sci, Chengdu 610072, Peoples R China [4]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Lab Med, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Peoples R China [6]Univ Elect Sci & Technol China, Sch Med, Chengdu 610047, Peoples R China [8]Yu Yue Pathol Sci Res Ctr, Chongqing 400039, Peoples R China [9]Jinfeng Lab, Chongqing 401329, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46425 今日访问量:0 总访问量:3323 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号